Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8 CAD | 0.00% |
|
-4.76% | -65.67% |
Valuation
Fiscal Period: June | 2021 | 2022 | 2023 |
---|---|---|---|
Capitalization 1 | 245.3 | 73.23 | 127.5 |
Enterprise Value (EV) 1 | 239.9 | 72.72 | 126.5 |
P/E ratio | -65.6 x | -9.83 x | -17.1 x |
Yield | - | - | - |
Capitalization / Revenue | - | - | - |
EV / Revenue | - | - | - |
EV / EBITDA | - | - | -19,519,801 x |
EV / FCF | -200,500,528 x | -22,400,014 x | -23,681,510 x |
FCF Yield | -0% | -0% | -0% |
Price to Book | 45.3 x | -189 x | 81.6 x |
Nbr of stocks (in thousands) | 34,801 | 36,615 | 43,681 |
Reference price 2 | 7.050 | 2.000 | 2.920 |
Announcement Date | 27/10/21 | 24/10/22 | 27/10/23 |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Net sales | - | - | - | - | - |
EBITDA | - | - | - | - | -6.481 |
EBIT 1 | -0.0419 | -0.6732 | -2.826 | -7.274 | -6.494 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -0.001946 | -0.6732 | -2.859 | -7.344 | -6.868 |
Net income 1 | -0.001946 | -0.6732 | -2.859 | -7.344 | -6.763 |
Net margin | - | - | - | - | - |
EPS | - | -0.7137 | -0.1075 | -0.2036 | -0.1705 |
Free Cash Flow | - | -0.2393 | -1.196 | -3.247 | -5.342 |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 02/02/21 | 02/02/21 | 27/10/21 | 24/10/22 | 27/10/23 |
Balance Sheet Analysis
Fiscal Period: Juni | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - |
Net Cash position 1 | 0 | 1.87 | 5.45 | 0.51 | 1.05 |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow | - | -0.24 | -1.2 | -3.25 | -5.34 |
ROE (net income / shareholders' equity) | - | -72.2% | -77.8% | -288% | -1,148% |
ROA (Net income/ Total Assets) | - | -43.8% | -47% | -144% | -191% |
Assets 1 | - | 1.536 | 6.088 | 5.112 | 3.542 |
Book Value Per Share | - | 0.1000 | 0.1600 | -0.0100 | 0.0400 |
Cash Flow per Share | - | 0.1000 | 0.1500 | 0.0100 | 0.0600 |
Capex | - | - | - | - | 0.07 |
Capex / Sales | - | - | - | - | - |
Announcement Date | 02/02/21 | 02/02/21 | 27/10/21 | 24/10/22 | 27/10/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-65.67% | 26.6M | |
+17.72% | 44.87B | |
-10.33% | 37.8B | |
+40.40% | 37.61B | |
+29.36% | 31.32B | |
-8.44% | 27.4B | |
+12.45% | 26.32B | |
+44.19% | 14.07B | |
+31.93% | 12.5B | |
-7.67% | 11.23B |
- Stock Market
- Equities
- DTC Stock
- Financials Defence Therapeutics Inc.